Golimumab: TNF alpha antibody for rheumatology and ulcerative colitis
Golimumab (brand name Simponi, also Simponi Aria) is a fully human IgG1 kappa monoclonal antibody that binds and neutralises tumour necrosis factor alpha (TNF alpha). Approved by the EMA in 2009, golimumab is part of the anti TNF class alongside infliximab, adalimumab, etanercept and certolizumab pegol. Compared with older anti TNF agents, golimumab offers monthly subcutaneous self-injection (50 mg). For ulcerative colitis an intravenous formulation (Simponi Aria) is also available.
Mechanism of action
TNF alpha is a key driver of chronic inflammation, released by macrophages and T cells. Through TNFR1 and TNFR2 it activates NF-kappa B and MAP kinase pathways, releasing further inflammatory cytokines, adhesion molecules and matrix metalloproteinases. In synovium, gut mucosa and skin this drives joint destruction, ulceration and plaque formation. Golimumab binds soluble and membrane-bound TNF alpha with high affinity, blocking the downstream cascade. Clinically this brings rapid symptom relief, lower CRP, slowed radiographic progression and mucosal healing in ulcerative colitis.
Indications
- Rheumatoid arthritis (RA): moderate to severe disease, with methotrexate
- Psoriatic arthritis: active and progressive forms after DMARD failure
- Axial spondyloarthritis: ankylosing spondylitis and non-radiographic axial SpA
- Ulcerative colitis: moderate to severe disease in adults
- Polyarticular juvenile idiopathic arthritis: from age 2 with insufficient response to methotrexate
Dosing
Subcutaneous (Simponi): 50 mg once monthly; in patients above 100 kg with insufficient response 100 mg monthly.
Ulcerative colitis IV (Simponi Aria): 200 mg week 0, 100 mg week 2, then 100 mg every 4 weeks. Subcutaneous induction 200 mg week 0, 100 mg week 2, then 50 mg or 100 mg every 4 weeks depending on weight.
Subcutaneous injection into thigh or abdomen, rotating sites. Bring solution to room temperature for 30 minutes before injection.
Side effects
Very common: upper respiratory tract infections, injection site reactions.
Common: bacterial infections, sinusitis, bronchitis, herpes zoster, anaemia, allergic reactions, headache, hypertension, raised liver enzymes, rash.
Uncommon: opportunistic infections (tuberculosis reactivation, invasive mycoses), paradoxical psoriasis, lupus-like reactions, demyelination, leukopenia, worsened heart failure, pancreatitis.
Rare: lymphoma (especially hepatosplenic T cell lymphoma in young men on anti TNF plus thiopurine), vasculitis, hepatitis, severe allergic reactions.
Key warnings: screen for latent tuberculosis (Quantiferon, chest X ray) and hepatitis B before starting; live vaccines are contraindicated; pause therapy during severe infections.
Interactions
- Other biologics (anakinra, abatacept, rituximab): increased infection risk, combination not recommended
- Live vaccines: contraindicated during therapy and for several months afterwards
- CYP450 substrates: reduced cytokines may normalise enzyme activity; theophylline, warfarin, ciclosporin levels may need adjustment
- Methotrexate: useful combination; also reduces anti-drug antibody formation
Special considerations
Pregnancy: growing experience suggests no clear teratogenicity. Active placental transfer in the third trimester means live vaccines should be deferred in the infant for 6 to 12 months.
Breastfeeding: small amounts pass into breast milk, probably degraded in the infant gut; increasingly considered acceptable on individual benefit-risk.
Surgery: often paused for one or two dosing intervals before elective surgery and resumed after wound healing.
Therapy failure: trough levels and anti-drug antibodies can guide dose adjustment, switch to another anti TNF or class change.
Related substances
- Adalimumab, anti TNF with similar profile
- Infliximab, intravenous anti TNF
- Methotrexat, standard cDMARD in RA
- Tofacitinib, oral JAK inhibitor
Frequently asked questions
How does golimumab differ from adalimumab?
Both are human anti TNF antibodies. Adalimumab is injected every two weeks, golimumab once monthly. Clinically there are no major differences in efficacy or safety; choice depends on co-medication, indication spectrum and personal preference.
Is tuberculosis screening required before therapy?
Yes, this is mandatory. TNF alpha is essential for granuloma maintenance; anti TNF therapy can reactivate latent TB. History, Quantiferon and chest X ray are required before starting.
Can I travel with my golimumab pen?
Yes, the pen is stable for 30 days outside the fridge at room temperature. A medical travel letter helps at borders. For high-risk regions, a travel-medicine consultation is sensible.
What if golimumab stops working after years?
Secondary loss of response affects roughly a third of patients within five years, often due to anti-drug antibodies. Trough levels guide dose increase, switch to another anti TNF, JAK inhibitor or other biologic.
Sources
- EMA Simponi (golimumab) EPAR
- BfArM
- AWMF guidelines RA and ulcerative colitis
- Gelbe Liste golimumab monograph
Legal notice and disclaimer
The information on this page is provided for general information purposes only and does not constitute medical advice, diagnosis or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medicines should only be used after a doctor's prescription or pharmacy supply. All information is based on summaries of product characteristics and accepted scientific sources at the time of writing; the current SmPC of the manufacturer is always decisive. Sanoliste accepts no liability for completeness, timeliness or accuracy. In a medical emergency, dial the emergency number 112.